Belzutifan offers hope for patients with von Hippel-Lindau disease

The anti-cancer effect of the drug may help those with rare, hereditary cancer syndromes avoid surgeries by shrinking tumors via a daily oral dose.

5:00 AM

Author | Jordyn Imhoff

drawing in blue ink of kidneys on lined paper with lab note wording bottom right in blue with yellow background
Michigan Medicine

Patients with von Hippel–Lindau disease, a genetic condition brought on by a mutation in the VHL gene that predisposes the carrier to developing different kinds of tumors, have a high incidence of cancers, like kidney cancer. This is because of an inactive VHL gene that leads to hypoxia signaling, a condition that results from an imbalance between cellular oxygen consumption and blood flow.

Traditionally, invasive procedures like kidney and brain surgery were the only option for patients who produce these tumors, but an international single-group study of 61 participants published in The New England Journal of Medicine offers hope for those with the rare disease with the drug Belzutifan, which the research team showed can shrink tumors and keep patients from having to undergo surgery.

The drug, which targets the molecular defect in the VHL gene by antagonizing the hypoxia signaling, produces few side effects (predominantly anemia and/or fatigue) and appears to have an anti-cancer effect, according to study author Tobias Else, M.D., an endocrinologist leading the Comprehensive Clinical Care Center for VHL at University of Michigan Health Rogel Cancer Center.

"In virtually all of the patients' kidney cancers, brain and pancreatic tumors, the tumors shrunk and the effect was long lasting," said Else.

These findings are especially important for patients who are at higher risk of losing vital organ function due to tumors, or who face this risk due to the need to undergo major surgery. Belzutifan provides an alternative to surgery and may even replace it at some point, which is Else's hope.

"Ongoing studies will further evaluate the effect of this drug on these patients' tumors, but this is an exciting start for anyone with a hereditary cancer syndrome," said Else. "Rare diseases don't often get the attention they deserve, and this work shows that bench to bedside research can truly change peoples' lives. It may even lead to FDA approval of an entirely new in-class drug."

This research was sponsored by Peloton Therapeutics, Inc. and funded by Merck Sharp and Dohme, a subsidiary of Merck; the Intramural Research Program of the National Institutes of Health, National Cancer Institute Center for Cancer Research; and a grant (UO1 CA236489) from the NCI. Identifier: NCT03401788.

Paper cited: "Belzutifan for Renal Cell Carcinoma in von Hippel–Lindau Disease," The New England Journal of Medicine. DOI: 10.1056/NEJMoa2103425

More Articles About: Lab Notes Basic Science and Laboratory Research Alternative Medicine Cancer: Cancer Types Cancer and Genetics Cancer Surgery Cancer Research Cancer Treatment Genetics Rogel Cancer Center Kidney Cancer Surgery Types All Research Topics
Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of healthcare news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]


Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Featured News & Stories Jianping Fu, Ph.D., Professor of Mechanical Engineering at the University of Michigan and the corresponding author of the paper being published at Nature discusses his team’s work in their lab with Jeyoon Bok, Ph.D. candidate at the Department of Mechanical Engineering.
Health Lab
Human stem cells coaxed to mimic the very early central nervous system
The first organized stem cell culture model that resembles all three sections of the embryonic brain and spinal cord could shed light on developmental brain diseases
Health care provider with stethoscope holds patient's hand
Health Lab
Combatting prostate cancer stigma
Prostate cancer is highly treatable and over 98% of men survive 10 years if the cancer is diagnosed and treated early.
Illustration of a microscope
Health Lab
Hippo signaling pathway gives new insight into systemic sclerosis
Study focuses on Hippo signaling pathway as critical link between fibrosis, vascular dysfunction, and sex bias in systemic sclerosis
Headshot of Anne Draelos
Research News
U-M's Anne Draelos named a 2024 Sloan Research Fellow in neuroscience
Anne Draelos, Ph.D., Assistant Professor of Biomedical Engineering and Computational Medicine & Bioinformatics, has been named a 2024 Sloan Research Fellow in Neuroscience.
Woman in pink shirt lifts kettleball in an outdoor exercise class
Health Lab
How to make cancer prevention more equitable
Expert explains six behavioral risk factors for cancer and why current programs don’t always meet the needs of people from racially and ethnically minoritized groups and other vulnerable populations.
Don Reynolds, seated at right, and his family gather together. Reynolds can garden with his grandchildren after a successful treatment with Pluvicto. Photos courtesy of the Reynolds family
Health Lab
Pluvicto treatment gives patient another chance
New treatment for metastatic castration resistant prostate cancer helped patient get back to his hobbies